• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary: Guselkumab binding to CD64 IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling.

作者信息

Valdiserra Giulia, Di Salvo Clelia, Fornai Matteo, Antonioli Luca

机构信息

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

出版信息

Front Immunol. 2025 May 20;16:1604337. doi: 10.3389/fimmu.2025.1604337. eCollection 2025.

DOI:10.3389/fimmu.2025.1604337
PMID:40463376
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12129961/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c21/12129961/0d028fe976f0/fimmu-16-1604337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c21/12129961/0d028fe976f0/fimmu-16-1604337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c21/12129961/0d028fe976f0/fimmu-16-1604337-g001.jpg

相似文献

1
Commentary: Guselkumab binding to CD64 IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling.评论：古塞库单抗与产生白细胞介素-23的髓样细胞表面的CD64结合，增强了中和白细胞介素-23信号传导的效力。
Front Immunol. 2025 May 20;16:1604337. doi: 10.3389/fimmu.2025.1604337. eCollection 2025.
2
Guselkumab binding to CD64 IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling.古塞库单抗与产生白细胞介素-23的髓样细胞上的CD64结合，增强了中和白细胞介素-23信号传导的效力。
Front Immunol. 2025 Mar 12;16:1532852. doi: 10.3389/fimmu.2025.1532852. eCollection 2025.
3
Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy.在银屑病患者中，古塞库单抗比阿达木单抗更能降低疾病及机制相关生物标志物：VOYAGE 1子研究
JID Innov. 2024 Jun 5;4(5):100287. doi: 10.1016/j.xjidi.2024.100287. eCollection 2024 Sep.
4
Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab.在使用古塞单抗与司库珠单抗治疗银屑病过程中，皮肤中炎症性单核吞噬细胞和 T 细胞表型的差异变化。
J Invest Dermatol. 2021 Jul;141(7):1707-1718.e9. doi: 10.1016/j.jid.2021.01.005. Epub 2021 Jan 30.
5
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?
Expert Opin Biol Ther. 2025 Jun;25(6):593-598. doi: 10.1080/14712598.2025.2508836. Epub 2025 May 21.
6
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.接受古塞库单抗与皮下注射白细胞介素-17A抑制剂治疗的银屑病关节炎真实世界患者的标签内治疗持续性比较
Adv Ther. 2025 Feb;42(2):734-751. doi: 10.1007/s12325-024-03042-1. Epub 2024 Dec 2.
7
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Guselkumab 调节生物制剂初治患者与肿瘤坏死因子抑制剂应答不足的活动性银屑病关节炎患者的白细胞介素-23 信号通路。
Arthritis Rheumatol. 2024 Jun;76(6):894-904. doi: 10.1002/art.42803. Epub 2024 Mar 4.
8
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.古塞库单抗，一种白细胞介素-23p19 亚单位抑制剂，为活动性银屑病关节炎的体征和症状提供持续改善：一项对生物初治或 TNFα 抑制剂经治患者进行的 III 期随机研究的 1 年结果。
RMD Open. 2021 Feb;7(1). doi: 10.1136/rmdopen-2020-001457.
9
Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial.活动性银屑病关节炎患者中炎症和胶原蛋白生物标志物变化与古塞库单抗长达2年的持久疗效的相关性：一项III期随机对照试验的结果
Ther Adv Musculoskelet Dis. 2024 Oct 27;16:1759720X241283536. doi: 10.1177/1759720X241283536. eCollection 2024.
10
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.古塞库单抗对肿瘤坏死因子抑制剂治疗应答不足的活动性银屑病关节炎患者血清生物标志物的影响：来自 COSMOS 期 3b 研究的结果。
Arthritis Res Ther. 2023 Aug 16;25(1):150. doi: 10.1186/s13075-023-03125-4.

本文引用的文献

1
Guselkumab binding to CD64 IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling.古塞库单抗与产生白细胞介素-23的髓样细胞上的CD64结合，增强了中和白细胞介素-23信号传导的效力。
Front Immunol. 2025 Mar 12;16:1532852. doi: 10.3389/fimmu.2025.1532852. eCollection 2025.
2
Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells.17 型免疫：肠道初免 T 细胞驱动的肠道稳态和自身免疫发病机制的新见解。
Cell Mol Immunol. 2024 Nov;21(11):1183-1200. doi: 10.1038/s41423-024-01218-x. Epub 2024 Oct 8.
3
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.
IL-23 的过去、现在和未来：推进 IL-23 科学和治疗的路线图。
Front Immunol. 2024 Apr 15;15:1331217. doi: 10.3389/fimmu.2024.1331217. eCollection 2024.
4
Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer.靶向自身免疫性疾病、神经病变和癌症中的高亲和力受体FcγRI。
Immunother Adv. 2022 May 28;2(1):ltac011. doi: 10.1093/immadv/ltac011. eCollection 2022.
5
A non-clinical comparative study of IL-23 antibodies in psoriasis.一项关于银屑病中白细胞介素 23 抗体的非临床对照研究。
MAbs. 2021 Jan-Dec;13(1):1964420. doi: 10.1080/19420862.2021.1964420.
6
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs.通过标志性细胞因子中心重塑免疫介导的炎症性疾病
N Engl J Med. 2021 Aug 12;385(7):628-639. doi: 10.1056/NEJMra1909094.
7
Origin and Differentiation of Nerve-Associated Macrophages.神经相关巨噬细胞的起源与分化。
J Immunol. 2020 Jan 15;204(2):271-279. doi: 10.4049/jimmunol.1901077.
8
Neuronal FcγRI mediates acute and chronic joint pain.神经元 FcγRI 介导急性和慢性关节痛。
J Clin Invest. 2019 Jun 18;129(9):3754-3769. doi: 10.1172/JCI128010.
9
Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I.免疫球蛋白G通过Fcγ受体I对初级感觉神经元的直接作用。
FASEB J. 2004 Jan;18(1):182-4. doi: 10.1096/fj.02-1169fje. Epub 2003 Nov 20.